Core Viewpoint - The chairman of New Mileage, Lin Yanglin, is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties. The company stated that the matter is unrelated to its operations and has not been asked to assist in the investigation [1]. Group 1: Company Operations - New Mileage's main business segments include medical services and traditional Chinese medicine, with medical services accounting for approximately 80% of its revenue [2]. - In 2024, New Mileage reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan [1]. - The company operates six regional medical centers across various provinces and has a total of 24 hospitals, including three tertiary hospitals and 14 secondary or higher-level hospitals [2]. Group 2: Corporate Structure and History - New Mileage's pharmaceutical business is primarily centered around the "Duyiwei" brand of traditional Chinese medicine, which contributes about 20% to its revenue [4]. - The company was formerly known as Hengkang Medical and became controlled by Beijing New Mileage Health Industry Group in 2022 [4]. - New Mileage Group manages over 40 hospitals across nearly 20 provinces, with a total bed capacity of 30,000, ranking among the top three in the country [4]. Group 3: Financial and Regulatory Issues - On June 20, Lin Yanglin and the CFO Liu Jun were subjected to regulatory discussions by the Gansu Securities Regulatory Bureau due to non-compliance with accounting standards related to stock incentive plans and construction project accounting [6]. - The financial discrepancies have led to inaccurate disclosures in the consolidated balance sheets for the fiscal years 2023 and the first three quarters of 2024, violating the regulations on information disclosure for listed companies [6].